losartan has been researched along with Brain Vascular Disorders in 17 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| " We aimed to compare the risks of myocardial infarction (MI), heart failure (HF), and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan with different half-lives in a national claim-based retrospective cohort of patients aged ≥ 40 years with hypertension." | 8.31 | Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients. ( Jeong, HE; Kim, JS; Ko, H; Lim, MJ; Shin, JY; Yoo, YG, 2023) |
| " The purpose of the present exploratory study was to determine whether blood pressure-lowering therapy with the combination of the angiotensin receptor blocker losartan plus hydrochlorothiazide (LPH) worsens brain perfusion in patients with both hypertension and cerebral hemodynamic impairment due to symptomatic chronic major cerebral artery steno-occlusive disease." | 7.78 | Effect of combination therapy with the angiotensin receptor blocker losartan plus hydrochlorothiazide on brain perfusion in patients with both hypertension and cerebral hemodynamic impairment due to symptomatic chronic major cerebral artery steno-occlusiv ( Kobayashi, M; Kuroda, H; Ogasawara, K; Ogawa, A; Saura, H; Suzuki, T; Terasaki, K; Yamashita, T, 2012) |
| " We tested the curative potential of the non brain-penetrant ACEi enalapril (3 mg/kg/day) administered for 3 months either alone or in combination with the brain penetrant ARB losartan (10 mg/kg/day) in aged (∼15 months) transgenic mice overexpressing a mutated form of the human amyloid-β protein precursor (AβPP, thereafter APP mice)." | 5.43 | Enalapril Alone or Co-Administered with Losartan Rescues Cerebrovascular Dysfunction, but not Mnemonic Deficits or Amyloidosis in a Mouse Model of Alzheimer's Disease. ( Aboulkassim, T; Hamel, E; Imboden, H; Nicolakakis, N; Ongali, B; Tong, XK, 2016) |
| " We aimed to compare the risks of myocardial infarction (MI), heart failure (HF), and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan with different half-lives in a national claim-based retrospective cohort of patients aged ≥ 40 years with hypertension." | 4.31 | Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients. ( Jeong, HE; Kim, JS; Ko, H; Lim, MJ; Shin, JY; Yoo, YG, 2023) |
| " The purpose of the present exploratory study was to determine whether blood pressure-lowering therapy with the combination of the angiotensin receptor blocker losartan plus hydrochlorothiazide (LPH) worsens brain perfusion in patients with both hypertension and cerebral hemodynamic impairment due to symptomatic chronic major cerebral artery steno-occlusive disease." | 3.78 | Effect of combination therapy with the angiotensin receptor blocker losartan plus hydrochlorothiazide on brain perfusion in patients with both hypertension and cerebral hemodynamic impairment due to symptomatic chronic major cerebral artery steno-occlusiv ( Kobayashi, M; Kuroda, H; Ogasawara, K; Ogawa, A; Saura, H; Suzuki, T; Terasaki, K; Yamashita, T, 2012) |
| "Oral losartan at 30 mg/kg per day delayed the development of severe hypertension and prevented stroke in saline-drinking SHRSP." | 3.68 | Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats. ( Adler, LA; Chander, PN; Levine, S; Stier, CT, 1993) |
| "To study the effects of blockade of the renin-angiotensin system upon the development of hypertension, end-organ damage and mortality in Dahl salt-sensitive (DSS) rats using an angiotensin II receptor antagonist, losartan." | 3.68 | Angiotensin II receptor antagonist delays renal damage and stroke in salt-loaded Dahl salt-sensitive rats. ( Camargo, MJ; Campbell, WG; Laragh, JH; Mueller, FB; Sealey, JE; Timmermans, PB; von Lutterotti, N, 1992) |
| " We tested the curative potential of the non brain-penetrant ACEi enalapril (3 mg/kg/day) administered for 3 months either alone or in combination with the brain penetrant ARB losartan (10 mg/kg/day) in aged (∼15 months) transgenic mice overexpressing a mutated form of the human amyloid-β protein precursor (AβPP, thereafter APP mice)." | 1.43 | Enalapril Alone or Co-Administered with Losartan Rescues Cerebrovascular Dysfunction, but not Mnemonic Deficits or Amyloidosis in a Mouse Model of Alzheimer's Disease. ( Aboulkassim, T; Hamel, E; Imboden, H; Nicolakakis, N; Ongali, B; Tong, XK, 2016) |
| "To investigate in young salt-loaded stroke-prone spontaneously hypertensive rats (SHR-SP) the effects of a long-term administration of the angiotensin II AT1 receptor antagonist losartan [1 mg/kg (L1) and 10 mg/kg (L10) per day, from 5 to 20 weeks of age] on the structural and functional characteristics of the middle cerebral artery." | 1.29 | Effects of losartan on cerebral arteries in stroke-prone spontaneously hypertensive rats. ( Giudicelli, JF; Richer, C; Vacher, E, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (70.59) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 2 (11.76) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Yoo, YG | 1 |
| Lim, MJ | 1 |
| Kim, JS | 1 |
| Jeong, HE | 1 |
| Ko, H | 1 |
| Shin, JY | 1 |
| Ongali, B | 1 |
| Nicolakakis, N | 1 |
| Tong, XK | 1 |
| Aboulkassim, T | 1 |
| Imboden, H | 1 |
| Hamel, E | 1 |
| Saura, H | 1 |
| Ogasawara, K | 1 |
| Suzuki, T | 1 |
| Kuroda, H | 1 |
| Yamashita, T | 1 |
| Kobayashi, M | 1 |
| Terasaki, K | 1 |
| Ogawa, A | 1 |
| de Boer, RA | 1 |
| van Veldhuisen, DJ | 1 |
| Gans, RO | 1 |
| Gansevoort, RT | 1 |
| Arrick, DM | 1 |
| Sharpe, GM | 1 |
| Sun, H | 1 |
| Mayhan, WG | 1 |
| Fornes, P | 1 |
| Richer, C | 2 |
| Vacher, E | 2 |
| Bruneval, P | 1 |
| Giudicelli, JF | 2 |
| Stier, CT | 1 |
| Adler, LA | 1 |
| Levine, S | 1 |
| Chander, PN | 1 |
| Nagura, J | 1 |
| Hui, C | 1 |
| Yamamoto, M | 1 |
| Yasuda, S | 1 |
| Abe, M | 1 |
| Hachisu, M | 1 |
| Konno, F | 1 |
| Gohlke, P | 2 |
| Linz, W | 1 |
| Schölkens, BA | 1 |
| Wiemer, G | 1 |
| Unger, T | 2 |
| Krasnikova, TL | 1 |
| Yo, Y | 1 |
| Moriguchi, A | 1 |
| Higaki, J | 1 |
| Nagano, M | 1 |
| Nakano, N | 1 |
| Kamide, K | 1 |
| Yu, H | 1 |
| Mikami, H | 1 |
| Ogihara, T | 1 |
| Pees, C | 1 |
| Wagner, J | 1 |
| Drab, M | 1 |
| Bohlender, J | 1 |
| Amann, K | 1 |
| Wienen, W | 1 |
| Ganten, D | 1 |
| Nishikawa, K | 1 |
| von Lutterotti, N | 2 |
| Camargo, MJ | 2 |
| Campbell, WG | 1 |
| Mueller, FB | 1 |
| Timmermans, PB | 2 |
| Sealey, JE | 1 |
| Laragh, JH | 2 |
| Pecker, MS | 1 |
| James, GD | 1 |
2 reviews available for losartan and Brain Vascular Disorders
| Article | Year |
|---|---|
[Losartan, an angiotensin II receptor blocker: a new trend in cardiovascular chemotherapy].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun | 1996 |
Angiotensin AT1 receptor antagonism and protection against cardiovascular end-organ damage.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 1998 |
15 other studies available for losartan and Brain Vascular Disorders
| Article | Year |
|---|---|
Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl | 2023 |
Enalapril Alone or Co-Administered with Losartan Rescues Cerebrovascular Dysfunction, but not Mnemonic Deficits or Amyloidosis in a Mouse Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloidosis; Analysis of V | 2016 |
Effect of combination therapy with the angiotensin receptor blocker losartan plus hydrochlorothiazide on brain perfusion in patients with both hypertension and cerebral hemodynamic impairment due to symptomatic chronic major cerebral artery steno-occlusiv
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arterial Occlusive Di | 2012 |
[Treatment of hypertension: angiotensin-II antagonists potentially better than beta-blockers in the occurrence of cardiovascular and cerebrovascular damage; the LIFE study in perspective].
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agen | 2003 |
Losartan improves impaired nitric oxide synthase-dependent dilatation of cerebral arterioles in type 1 diabetic rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Arterioles; Cerebral Arteries; Cerebrovascular Dis | 2008 |
Losartan's protective effects in stroke-prone spontaneously hypertensive rats persist durably after treatment withdrawal.
Topics: Aging; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood | 1993 |
Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Cerebrovascu | 1993 |
ME3221, a surmountable angiotensin AT1-receptor antagonist, prevents hypertensive complications in aged stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressu | 1996 |
Cardiac and vascular effects of long-term losartan treatment in stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Blood Vessels; Body W | 1996 |
Effects of losartan on cerebral arteries in stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cerebral Arteries; Ce | 1996 |
Renal effects of an angiotensin II antagonist in stroke-prone spontaneously hypertensive rat.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood | 1997 |
AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism.
Topics: Angiotensin II; Animals; Aorta; Blood Pressure; Bradykinin; Bradykinin Receptor Antagonists; Cerebro | 1998 |
Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensin | 1998 |
Angiotensin II receptor antagonist delays renal damage and stroke in salt-loaded Dahl salt-sensitive rats.
Topics: Angiotensin II; Animals; Biphenyl Compounds; Blood Pressure; Cerebrovascular Disorders; Hypertension | 1992 |
DuP 753 increases survival in spontaneously hypertensive stroke-prone rats fed a high sodium diet.
Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Body Weight; Cerebrovascular Disorders; D | 1991 |